Suppr超能文献

肾离子转运体对慢性利尿剂治疗的长期适应性

Long-term adaptation of renal ion transporters to chronic diuretic treatment.

作者信息

Kim Gheun-Ho

机构信息

Department of Internal Medicine and Institute of Biomedical Sciences, Hanyang University College of Medicine, Seoul, Korea.

出版信息

Am J Nephrol. 2004 Nov-Dec;24(6):595-605. doi: 10.1159/000082314. Epub 2004 Nov 23.

Abstract

Loop and thiazide diuretics are clinically useful to induce negative sodium balance. However, with chronic treatment, their effects tend to be blunted since the kidney adapts to diuretics. Molecular identification of the renal ion transporters has provided us with a new understanding of the mechanisms of intrarenal adaptation to diuretics at molecular levels. In the kidney, loop and thiazide diuretics are secreted from the proximal tubule via the organic anion transporter-1 (OAT1) and exert their diuretic action by binding to the Na-K-2Cl cotransporter type 2 (NKCC2) in the thick ascending limb and the Na-Cl cotransporter (NCC) in the distal convoluted tubule, respectively. Recent studies in animal models suggest that abundance of these ion transporters is affected by long-term diuretic administration. Downstream from the primary site of diuretic action, an increase in epithelial Na+ channel (ENaC) abundance is induced by chronic furosemide or hydrochlorothiazide treatment. This adaptation is consistent with previous reports showing cellular hypertrophy and increased Na+ absorption in distal tubular segments. The abundance of NKCC2 and NCC is increased by furosemide and hydrochlorothiazide, respectively. This compensatory upregulation suggests that either diuretic may activate the ion transporter within the primary site of action. In the proximal tubule, the abundance of OAT1 is increased by chronic treatment with furosemide or hydrochlorothiazide. This upregulation of OAT1 seems to be induced by substrate stimulation, lessening diuretic tolerance associated with long-term diuretic use.

摘要

袢利尿剂和噻嗪类利尿剂在临床上可有效诱导负钠平衡。然而,长期使用时,由于肾脏会适应利尿剂,其效果往往会减弱。肾脏离子转运体的分子鉴定使我们对肾脏在分子水平上适应利尿剂的机制有了新的认识。在肾脏中,袢利尿剂和噻嗪类利尿剂通过有机阴离子转运体-1(OAT1)从近端小管分泌,并分别通过与髓袢升支粗段的钠-钾-2氯协同转运体2(NKCC2)和远曲小管的钠-氯协同转运体(NCC)结合来发挥利尿作用。最近在动物模型中的研究表明,长期使用利尿剂会影响这些离子转运体的丰度。在利尿作用的主要部位下游,长期使用呋塞米或氢氯噻嗪治疗可诱导上皮钠通道(ENaC)丰度增加。这种适应性变化与先前报道的远曲小管节段细胞肥大和钠吸收增加一致。呋塞米和氢氯噻嗪分别增加了NKCC2和NCC的丰度。这种代偿性上调表明,这两种利尿剂都可能在主要作用部位激活离子转运体。在近端小管中,长期使用呋塞米或氢氯噻嗪治疗可增加OAT1的丰度。OAT1的这种上调似乎是由底物刺激诱导的,从而减轻了与长期使用利尿剂相关的利尿耐受性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验